Idorsia Ltd. · SIX:IDIA
Idorsia — H1 2025 Earnings Presentation
26 slides from Idorsia's earnings presentation, Jul 30, 2025
Slide 1: Idorsia – Advancing towards profitability
Idorsia – Advancing towards profitability Half-year Financial Reporting – Investor webcast – July 2025
Slide 2: Forward-looking statements
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "s
Slide 3: CEO quote on commercial acceleration and profitability
“The commercial acceleration of QUVIVIQ, combined with our financial discipline, has put Idorsia on track to reach overall profitability starting from the end of 2027.” Srishti Gupta Chief Executive Officer 3 Idorsia – Advancing towards profitability | 30 Jul 2025
Slide 4: Highlights H1 2025
Highlights H1 2025 Idorsia-led QUVIVIQ Net sales • QUVIVIQ: unique product with rapidly growing sales and CHF 56 expanding global presence million • TRYVIO commercial opportunity significantly improved – engaging in partnership discussions 23 • Development pipeline prioritization complete – focused
Slide 5: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 5 Idorsia – Advancing towards profitability | 30 Jul 20
Slide 6: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 6 Idorsia – Advancing towards profitability | 30 Jul 20
Slide 7: QUVIVIQ is a key driver of Idorsia's path to profitability
QUVIVIQ is a key driver of Idorsia’s path to profitability… Strong positive feedback from Tailored to be best-in- Large market opportunity both healthcare professionals and class dual orexin receptor with significant growth patients confirming: antagonist (DORA) potential • Comprehensive sleep effic
Slide 8: … and is a growing global brand
… and is a growing global brand Europe - Approved Launched in: Switzerland France Germany Italy China Spain Sweden Approved and licensed North America United Kingdom to Simcere in China Launched in: Austria USA Finland Japan Canada MENA Launched and licensed to Nxera in Japan Licensed to CTS in Isra
Slide 9: QUVIVIQ sales are accelerating in Europe
QUVIVIQ sales are accelerating in Europe CHF EUCAN product sales • The only long-term pharmacological treatment for insomnia million 25.0 in Europe – on-track to become the standard of care • Newly launched in Finland 19.4 • Keys to success: − secure public reimbursement 13.9 − focused promotional e
Slide 10: Optimized approach implemented in the US while we work towards descheduling
Optimized approach implemented in the US while we work towards descheduling CHF million US product sales • Q1 2025: Implementation of a streamlined, 7.6 focused, and more cost-efficient virtual salesforce 7.1 7.3 approach • QUVIVIQ paid prescriptions now above 95% 5.9 5.9 • Target to maintain sales
Slide 11: We are generating evidence to support medical utility, especially in co-morbid conditions
We are generating evidence to support medical utility, especially in co-morbid conditions 2025 2026 2027 2028 2029 Major Depressive Disorder Post-Traumatic Stress Disorder Phase 2 in pediatric General Anxiety Disorder insomnia* Alcohol Use Disorder Alzheimer Disease Menopause Cognitive Performance C
Slide 12: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 12 Idorsia – Advancing towards profitability | 30 Jul 2
Slide 13: We have strong existing strategic alliances for our commercial and late-stage partnered assets
We have strong existing strategic alliances for our commercial and late-stage partnered assets 13 Idorsia – Advancing towards profitability | 30 Jul 2025
Slide 14: TRYVIO is the first and only ERA approved for systemic hypertension
TRYVIO is the first and only ERA approved for systemic hypertension Actively engaging in partnering discussions Unique indication based on compelling clinical efficacy and safety The first new drug class in systemic hypertension in decades Commercial opportunity significantly improved in H1 2025: •
Slide 15: We are exploring partnerships for Idorsia's synthetic glycan vaccine platform
We are exploring partnerships for Idorsia’s synthetic glycan vaccine platform • First-ever C. difficile vaccine directly targeting bacteria and spores • Initial Phase 1 data showing safety and immunogenicity • Study serves as clinical validation of synthetic glycan vaccine technology • Portfolio of
Slide 16: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 16 Idorsia – Advancing towards profitability | 30 Jul 2
Slide 17: Our key development assets at a glance
Our key development assets at a glance Asset Status Next milestones Lucerastat Phase 3 Regulatory pathway is under discussion Oral potential for organ protection Next steps in discussion with the FDA with the FDA in Fabry disease Daridorexant Phase 2 Recruitment expected to conclude by end of Dual o
Slide 18: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 18 Idorsia – Advancing towards profitability | 30 Jul 2
Slide 19: We have increased sales significantly while materially lowering OPEX
We have increased sales significantly while materially lowering OPEX H1 2024 in CHF millions, rounding differences may occur H1 2025 130 26 3 8 -4 -6 -61 -46 -15 -101 -134 -170 Net revenue Cost of sales R&D SG&A Other income Non-GAAP operating results Financial results as of Jun 30, 2025 19 Idorsia
Slide 20: US GAAP Profitability driven by the Viatris deal
US GAAP Profitability driven by the Viatris deal in CHF millions, rounding differences may occur H1 2025 89 64 52 -8 -4 -10 -15 Non-GAAP Viatris deal Other items US GAAP Financial Income tax US GAAP Net operating operating income expense income results result (expense) Financial results as of Jun 30
Slide 21: Our cash runway is now expected to run to the end of 2026
Our cash runway is now expected to run to the end of 2026 in CHF millions, rounding differences may occur 192* 58 -101 106 Product sales 70 72 -46 SG&A OPEX -15 R&D Liquidity OPEX Other 1st tranche Liquidity Jan 1, 2025 New Money Jun 30, 2025 Facility * Includes CHF 40 million milestone recognized i
Slide 22: Overall profitability is on the horizon
Overall profitability is on the horizon Status: July 2025 Guidance for 2025* CHF million Idorsia-led Partner-led Global business business Business REVENUE 130 75 205 COGS -15 - -15 SG&A OPEX -200 - -200 R&D OPEX -90 - -90 Non-GAAP EBIT -175 75 -100 Target commercial D&A -20 - -20 profitability in 20
Slide 23: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 23 Idorsia – Advancing towards profitability | 30 Jul 2
Slide 24: Highly qualified professionals
Highly qualified professionals Simply put – our success depends on our people! 24 Idorsia – Advancing towards profitability | 30 Jul 2025
Slide 25: Idorsia Executive Committee
Idorsia Executive Committee Arno Groenewoud Martine Clozel Julien Gander Srishti Gupta Alberto Gimona Chief Financial Officer Chief Scientific Officer Chief Legal & Corporate Chief Executive Officer Head of Global Clinical & Head of Research Development Officer Development & Medical Affairs 25 Idors
Slide 26: Key strategic priorities to ensure long-term success
+ Unlock the full value of QUVIVIQ + Expand strategic partnerships Key strategic priorities to + Advance our differentiated pipeline assets ensure long- term success + Operate with financial discipline + Empower our people to achieve excellence 26 Idorsia – Advancing towards profitability | 30 Jul 2